The Loterie Romande has awarded the foundation a grant to fund the development of its translational platform IT infrastructure.
This platform is currently under development and will facilitate:
- The systematic identification and evaluation of new therapeutic opportunities for rare diseases
- The standardized management of biomedical data generated during EspeRare’s development of new treatments
- Data sharing with external partners (patient groups, universities and pharmaceutical partners)
A first version of the translational platform will be launched by the end of the second quarter of 2014. Until December 2015, the performance of the platform will be optimized and other data sources such as libraries of pharmaceutical compounds from the NIH (National Institute of Health) will be integrated. This platform will promote the development of the EspeRare’s portfolio of projects in rare disease and will allow to manage data according to quality standards of the pharmaceutical industry and regulatory authorities.
Through its support, the Loterie Romande contributes to the development of the foundation’s activities, thus helping the foundation to expand its impact in addressing the healthcare burden of rare diseases.
About the Loterie Romande
